https://pittplusme.org/study/1322
HCC 18-42
STUDY BASICS
Have you been diagnosed with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer? Has your doctor recommended that you start taking brigatinib (brand name Alunbrig) to treat your disease? If so, you may be eligible to participate in this study to help researchers study how often pulmonary (lung) issues such as breathing issues, pneumonia, etc. occur to patients taking brigatinib.
IRB: STUDY19040116
- 18-042 Pulmonary Physiology and Systemic Inflammatory Signature Investigations in Early Onset Pulmonary Events Associated with Brigatinib use in Non-Small Cell Lung Cancer and Other Diseases
AGE:
18 and up
VISITS:
A screening visit and 4 in-person study visits
LOCATION:
UPMC Cancer Center
COMPENSATION:
NONE
SHARE STUDY
